MannKind Corp (MNKD)vsBeiGene, Ltd. (ONC)
MNKD
MannKind Corp
$2.28
-0.44%
HEALTHCARE · Cap: $702.47M
ONC
BeiGene, Ltd.
$283.45
+2.81%
HEALTHCARE · Cap: $31.62B
Smart Verdict
WallStSmart Research — data-driven comparison
BeiGene, Ltd. generates 1431% more annual revenue ($5.34B vs $348.97M). ONC leads profitability with a 5.4% profit margin vs 1.7%. ONC trades at a lower P/E of 111.0x. ONC earns a higher WallStSmart Score of 42/100 (D).
MNKD
Avoid35
out of 100
Grade: F
ONC
Hold42
out of 100
Grade: D
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-4000.0%
Fair Value
$0.14
Current Price
$2.28
$2.14 premium
Margin of Safety
-1983.5%
Fair Value
$16.86
Current Price
$283.45
$266.59 premium
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Revenue surging 45.8% year-over-year
Revenue surging 32.8% year-over-year
Conservative balance sheet, low leverage
Areas to Watch
Smaller company, higher risk/reward
ROE of 0.0% — below average capital efficiency
1.7% margin — thin
Expensive relative to growth rate
0.0% earnings growth
ROE of 7.5% — below average capital efficiency
5.4% margin — thin
Premium valuation, high expectations priced in
Comparative Analysis Report
WallStSmart ResearchBull Case : MNKD
The strongest argument for MNKD centers on Revenue Growth. Revenue growth of 45.8% demonstrates continued momentum.
Bull Case : ONC
The strongest argument for ONC centers on Revenue Growth, Debt/Equity. Revenue growth of 32.8% demonstrates continued momentum.
Bear Case : MNKD
The primary concerns for MNKD are Market Cap, Return on Equity, Profit Margin. A P/E of 114.0x leaves little room for execution misses. Thin 1.7% margins leave little buffer for downturns.
Bear Case : ONC
The primary concerns for ONC are EPS Growth, Return on Equity, Profit Margin. A P/E of 111.0x leaves little room for execution misses.
Key Dynamics to Monitor
MNKD carries more volatility with a beta of 0.93 — expect wider price swings.
MNKD is growing revenue faster at 45.8% — sustainability is the question.
ONC generates stronger free cash flow (131M), providing more financial flexibility.
Monitor BIOTECHNOLOGY industry trends, competitive dynamics, and regulatory changes.
Bottom Line
ONC scores higher overall (42/100 vs 35/100) and 32.8% revenue growth. Both earn "Hold" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
MannKind Corp
HEALTHCARE · BIOTECHNOLOGY · USA
MannKind Corporation, a biopharmaceutical company, focuses on the development and commercialization of inhaled therapeutics for endocrine and orphan lung diseases in the United States. The company is headquartered in Westlake Village, California.
BeiGene, Ltd.
HEALTHCARE · BIOTECHNOLOGY · USA
BeiGene, Ltd., an oncology company, engages in discovering and developing various treatments for cancer patients in the United States, China, Europe, and internationally. The company is headquartered in Camana Bay, the Cayman Islands.
Visit Website →Compare with Other BIOTECHNOLOGY Stocks
Want to dig deeper into these stocks?